NTLA
NASDAQIntellia Therapeutics Inc.
Price$11.38-0.25 (-2.15%)
01:30 PM07:45 PM
News · 26 weeks65-67%
2026-01-182026-07-12
Mix3390d
- SEC Filings10(30%)
- Insider9(27%)
- Other9(27%)
- Offering3(9%)
- Leadership1(3%)
- Earnings1(3%)
Latest news
25 items- ANALYSTIntellia Therapeutics downgraded by Wolfe Research with a new price targetWolfe Research downgraded Intellia Therapeutics from Peer Perform to Underperform and set a new price target of $9.00
- INSIDERVP, Chief Accounting Officer Dube Michael P sold $44,316 worth of shares (2,641 units at $16.78), decreasing direct ownership by 4% to 66,886 units (SEC Form 4) (tax liability)4 - Intellia Therapeutics, Inc. (0001652130) (Issuer)
- INSIDEREVP, Chief Financial Officer Dulac Edward J Iii sold $84,186 worth of shares (4,677 units at $18.00) as part of a pre-agreed trading plan, decreasing direct ownership by 3% to 156,286 units (SEC Form 4)4 - Intellia Therapeutics, Inc. (0001652130) (Issuer)
- PRIntellia Therapeutics Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)CAMBRIDGE, Mass., July 06, 2026 (GLOBE NEWSWIRE) -- Intellia Therapeutics, Inc. (NASDAQ:NTLA), a leading biopharmaceutical company focused on revolutionizing medicine leveraging CRISPR gene editing and other core technologies, today announced that on July 1, 2026, it awarded inducement grants to thirteen new employees under Intellia’s 2024 Inducement Plan, as amended, as a material inducement to employment. The inducement grants consisted of time-based restricted stock units ("RSUs") for an aggregate of 53,250 shares of Intellia’s common stock, with one-third of such RSUs vesting annually over three years. All equity vesting is subject to each employee’s continued service as an employee o
- SECIntellia Therapeutics Inc. filed SEC Form 8-K: Regulation FD Disclosure, Other Events, Financial Statements and Exhibits8-K - Intellia Therapeutics, Inc. (0001652130) (Filer)
- PRIntellia Therapeutics Reports Additional Positive Phase 3 Results for Lonvoguran Ziclumeran (lonvo-z) in Patients with Hereditary AngioedemaData from HAELO Phase 3 clinical trial presented today in a late-breaking oral session at European Academy of Allergy & Clinical Immunology Annual Congress 2026HAELO manuscript simultaneously published in the New England Journal of Medicine CAMBRIDGE, Mass., June 13, 2026 (GLOBE NEWSWIRE) -- Intellia Therapeutics, Inc. (NASDAQ:NTLA), a leading biopharmaceutical company focused on revolutionizing medicine leveraging CRISPR gene editing and other core technologies, today presented additional positive results from the global Phase 3 HAELO clinical trial of lonvo-z (formerly NTLA-2002) for hereditary angioedema (HAE) in a late-breaking oral presentation at the European Academy of Allergy & Cl
- INSIDERDirector Verwiel Frank was granted 9,200 shares, increasing direct ownership by 35% to 35,148 units (SEC Form 4)4 - Intellia Therapeutics, Inc. (0001652130) (Issuer)
- INSIDERDirector Keresty Georgia was granted 9,200 shares, increasing direct ownership by 29% to 41,083 units (SEC Form 4)4 - Intellia Therapeutics, Inc. (0001652130) (Issuer)
- INSIDERDirector Goodman Jesse was granted 9,200 shares, increasing direct ownership by 38% to 33,559 units (SEC Form 4)4 - Intellia Therapeutics, Inc. (0001652130) (Issuer)
- INSIDERDirector Goff Brian was granted 9,200 shares, increasing direct ownership by 39% to 32,609 units (SEC Form 4)4 - Intellia Therapeutics, Inc. (0001652130) (Issuer)
- INSIDERDirector Cohen Fred E was granted 9,200 shares, increasing direct ownership by 4% to 216,653 units (SEC Form 4)4 - Intellia Therapeutics, Inc. (0001652130) (Issuer)
- INSIDERDirector Chase William J was granted 9,200 shares, increasing direct ownership by 7% to 143,893 units (SEC Form 4)4 - Intellia Therapeutics, Inc. (0001652130) (Issuer)
- INSIDERDirector Bhanji Muna was granted 9,200 shares, increasing direct ownership by 34% to 36,403 units (SEC Form 4)4 - Intellia Therapeutics, Inc. (0001652130) (Issuer)
- SECIntellia Therapeutics Inc. filed SEC Form 8-K: Submission of Matters to a Vote of Security Holders8-K - Intellia Therapeutics, Inc. (0001652130) (Filer)
- PRIntellia Therapeutics Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)CAMBRIDGE, Mass., June 05, 2026 (GLOBE NEWSWIRE) -- Intellia Therapeutics, Inc. (NASDAQ:NTLA), a leading biopharmaceutical company focused on revolutionizing medicine leveraging CRISPR gene editing and other core technologies, today announced that on June 1, 2026, it awarded inducement grants to six new employees under Intellia's 2024 Inducement Plan, as amended, as a material inducement to employment. The inducement grants consisted of time-based restricted stock units ("RSUs") for an aggregate of 47,150 shares of Intellia's common stock, with one-third of such RSUs vesting annually over three years. All equity vesting is subject to each employee's continued service as an employee of, or
- PRIntellia Therapeutics to Report Additional Phase 3 HAELO Data for Lonvoguran Ziclumeran (lonvo-z) in Late-Breaking Oral Presentation at EAACI 2026CAMBRIDGE, Mass., June 01, 2026 (GLOBE NEWSWIRE) -- Intellia Therapeutics, Inc. (NASDAQ:NTLA), a leading biopharmaceutical company focused on revolutionizing medicine leveraging CRISPR gene editing and other core technologies, today announced that data from the global Phase 3 HAELO clinical trial of lonvo-z (formerly known as NTLA-2002) in hereditary angioedema (HAE) will be presented in a late-breaking oral presentation at the European Academy of Allergy & Clinical Immunology (EAACI) Annual Congress 2026, taking place June 12-15 in Istanbul, Türkiye. Intellia will also have a poster presentation detailing the burdens experienced by HAE patients living outside the United States. Late-Brea
- SECSEC Form 10-Q filed by Intellia Therapeutics Inc.10-Q - Intellia Therapeutics, Inc. (0001652130) (Filer)
- SECIntellia Therapeutics Inc. filed SEC Form 8-K: Results of Operations and Financial Condition, Financial Statements and Exhibits8-K - Intellia Therapeutics, Inc. (0001652130) (Filer)
- PRIntellia Therapeutics Announces First Quarter 2026 Financial Results and Business UpdatesPresented positive Phase 3 HAELO topline clinical data for lonvo-z in HAE; initiated rolling BLA submission; anticipate U.S. launch in first half of 2027Recently resumed patient screening in MAGNITUDE and MAGNITUDE-2 Phase 3 clinical trials of nex-z in ATTR-CM and ATTRv-PN, respectivelyIncluding proceeds from underwritten public offering in April, existing cash resources expected to fund operations at least into 2028 CAMBRIDGE, Mass., May 11, 2026 (GLOBE NEWSWIRE) -- Intellia Therapeutics, Inc. (NASDAQ:NTLA), a leading biopharmaceutical company focused on revolutionizing medicine leveraging CRISPR gene editing and other core technologies, today reported business updates and financial resu
- PRIntellia Therapeutics to Participate in Upcoming Investor ConferencesCAMBRIDGE, Mass., May 05, 2026 (GLOBE NEWSWIRE) -- Intellia Therapeutics, Inc. (NASDAQ:NTLA), a leading biopharmaceutical company focused on revolutionizing medicine leveraging CRISPR gene editing and other core technologies, today announced that management will be participating in fireside chats at the following upcoming investor conferences: Bank of America Securities Health Care ConferenceDate: Tuesday, May 12, 2026Fireside Chat Time: 3:40 p.m. PTLocation: Las Vegas RBC Capital Markets Global Healthcare ConferenceDate: Wednesday, May 20, 2026Fireside Chat Time: 2:35 p.m. ETLocation: New York Jefferies Global Healthcare ConferenceDate: Wednesday, June 3, 2026Fireside Chat Time: 4:55 p
- PRIntellia Therapeutics Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)CAMBRIDGE, Mass., May 01, 2026 (GLOBE NEWSWIRE) -- Intellia Therapeutics, Inc. (NASDAQ:NTLA), a leading biopharmaceutical company focused on revolutionizing medicine leveraging CRISPR gene editing and other core technologies, today announced that on May 1, 2026, it awarded inducement grants to 43 new employees under Intellia's 2024 Inducement Plan, as amended, as a material inducement to employment. The inducement grants consisted of time-based restricted stock units ("RSUs") for an aggregate of 208,850 shares of Intellia's common stock, with one-third of such RSUs vesting annually over three years. All equity vesting is subject to each employee's continued service as an employee of, or
- SECIntellia Therapeutics Inc. filed SEC Form 8-K: Results of Operations and Financial Condition8-K - Intellia Therapeutics, Inc. (0001652130) (Filer)
- SECSEC Form DEFA14A filed by Intellia Therapeutics Inc.DEFA14A - Intellia Therapeutics, Inc. (0001652130) (Filer)
- SECSEC Form DEF 14A filed by Intellia Therapeutics Inc.DEF 14A - Intellia Therapeutics, Inc. (0001652130) (Filer)
- SECSEC Form 424B5 filed by Intellia Therapeutics Inc.424B5 - Intellia Therapeutics, Inc. (0001652130) (Filer)
NTLA FAQ
7 questionsWhat does Intellia Therapeutics Inc. do?
Intellia Therapeutics, Inc., a genome editing company, focuses on the development of therapeutics. It utilizes a biological tool known as the Clustered, Regularly Interspaced Short Palindromic Repeats/CRISPR associated 9 (CRISPR/Cas9) system. The company's in vivo programs include NTLA-2001, which is in Phase 1 clinical trial for the treatment of transthyretin amyloidosis; and NTLA-2002 for the treatment of hereditary angioedema, as well as other liver-focused programs comprising hemophilia A and hemophilia B, hyperoxaluria Type 1, and alpha-1 antitrypsin deficiency. Its ex vivo pipeline...Where does NTLA stock trade?
Intellia Therapeutics Inc. (NTLA) is listed on NASDAQ.What sector and industry is NTLA in?
Intellia Therapeutics Inc. operates in the Health Care sector, Biotechnology: In Vitro & In Vivo Diagnostic Substances industry.When did Intellia Therapeutics Inc. go public?
Intellia Therapeutics Inc. (NTLA) completed its IPO in 2016.What are analysts saying about NTLA?
Intellia Therapeutics Inc. has had 8 recent analyst actions on file. The most recent action was from Wolfe Research: Underperform with a $900.00 price target on 2026-07-16. Recent price targets range from $500.00 to $1400.00.What companies are similar to NTLA?
Notable peers in the same industry include IDXX (IDEXX Laboratories Inc.), LNTH (Lantheus Holdings Inc.), ORKA (Oruka Therapeutics Inc.), OCDX (Ortho Clinical Diagnostics Holdings plc), CLDX (Celldex Therapeutics Inc.). Compare NTLA side-by-side with any of them on Quantisnow.How can I track NTLA on Quantisnow?
Quantisnow aggregates Intellia Therapeutics Inc.'s SEC filings, analyst ratings, insider transactions, FDA approvals, and press releases the moment they hit the wire (Wall Street's wire, on your screen.). Follow NTLA to receive live email and push alerts on every new disclosure.